Cytek Biosciences Balance Sheet Health
Financial Health criteria checks 5/6
Cytek Biosciences has a total shareholder equity of $385.5M and total debt of $3.2M, which brings its debt-to-equity ratio to 0.8%. Its total assets and total liabilities are $491.2M and $105.8M respectively.
Key information
0.8%
Debt to equity ratio
US$3.23m
Debt
| Interest coverage ratio | n/a |
| Cash | US$277.78m |
| Equity | US$385.46m |
| Total liabilities | US$105.76m |
| Total assets | US$491.23m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 8EQ's short term assets ($390.2M) exceed its short term liabilities ($62.8M).
Long Term Liabilities: 8EQ's short term assets ($390.2M) exceed its long term liabilities ($43.0M).
Debt to Equity History and Analysis
Debt Level: 8EQ has more cash than its total debt.
Reducing Debt: Insufficient data to determine if 8EQ's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable 8EQ has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: 8EQ is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 8.5% per year.